203390
(±)-Blebbistatin
≥97% (HPLC), solid, Myosin II inhibitor, Calbiochem®
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
(±)-Blebbistatin
Empirical Formula (Hill Notation):
C18H16N2O2
Recommended Products
Quality Level
Assay
≥97% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
color
yellow
solubility
methanol: 1.5 mg/mL
100% DMSO: 100 mg/mL
90% DMSO: 75 mg/mL
shipped in
wet ice
storage temp.
−20°C
InChI
1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3
InChI key
LZAXPYOBKSJSEX-UHFFFAOYSA-N
General description
A cell-permeable compound that acts as a selective, potent, and reversible inhibitor of non-muscle myosin II. Inhibits the ATPase and gliding motility of human platelets (≤100 µM) without affecting myosin light chain kinase (MLCK) activity. Has been shown to block cell blebbing and to rapidly disrupt directed cell migration and cytokinesis in vertebrate cells. Does not disrupt mitosis or affect contractile ring assembly.
A cell-permeable compound that acts as a selective, potent, and reversible inhibitor of nonmuscle myosin II. Inhibits the ATPase and gliding motility of human platelets (≤ 100 µM) without affecting myosin light chain kinase (MLCK) activity. Has been shown to block cell blebbing and to rapidly disrupt directed cell migration and cytokinesis in vertebrate cells. Does not disrupt mitosis or affect contractile ring assembly. A 50 mM (5 mg/342 µl) solution of (±)-Blebbistatin (Cat. No. 203389) in 90% DMSO is also available.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
ATPase
ATPase
Product does not compete with ATP.
Reversible: yes
Target IC50: <100 µM inhibiting the ATPase and gliding motility of human platelets
Packaging
Packaged under inert gas
Reconstitution
Following reconstitution in 90% DMSO, aliquot and freeze (-20°C). Stock solutions in 90% DMSO are stable for up to 1 month at -20°C. Stock solutions in 100% DMSO are unstable; reconstitute just prior to use.
Other Notes
Shu, S., et al. 2005. Proc. Natl. Acad. Sci. USA102, 1472.
Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003. Science299, 1743.
Cheung, A., et al. 2001. Mol. Biol. Cell Suppl.12, 271a.
Kovacs, M., et al. 2004. J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003. Science299, 1743.
Cheung, A., et al. 2001. Mol. Biol. Cell Suppl.12, 271a.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Antonios Georgantzoglou et al.
The Journal of cell biology, 221(8) (2022-06-23)
Migrating cells must interpret chemical gradients to guide themselves within tissues. A long-held principle is that gradients guide cells via reorientation of leading-edge protrusions. However, recent evidence indicates that protrusions can be dispensable for locomotion in some contexts, raising questions
Sarah Escuin et al.
Disease models & mechanisms, 16(3) (2023-03-15)
Understanding the molecular mechanisms that lead to birth defects is an important step towards improved primary prevention. Mouse embryos homozygous for the Kumba (Ku) mutant allele of Zic2 develop severe spina bifida with complete lack of dorsolateral hinge points (DLHPs)
Ling-Yea Yu et al.
Bio-protocol, 13(21), e4867-e4867 (2023-11-16)
Cell signaling is highly integrated for the process of various cell activities. Although previous studies have shown how individual genes contribute to cell migration, it remains unclear how the integration of these signaling pathways is involved in the modulation of
Mark Sweeney et al.
International journal of molecular sciences, 24(16) (2023-08-26)
Cardiac fibrosis is a common pathological process in heart disease, representing a therapeutic target. Transforming growth factor β (TGFβ) is the canonical driver of cardiac fibrosis and was recently shown to be dependent on interleukin 11 (IL11) for its profibrotic
Qingyu Xu et al.
Nature communications, 14(1), 1497-1497 (2023-03-19)
Limited response rates and frequent relapses during standard of care with hypomethylating agents in myelodysplastic neoplasms (MN) require urgent improvement of this treatment indication. Here, by combining 5-azacytidine (5-AZA) with the pan-lysyl oxidase inhibitor PXS-5505, we demonstrate superior restoration of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service